Saccomano Nicholas A's Form 4 filing
OnKure Therapeutics, Inc. (OKUR) · filed Aug 11, 2026
- Accession no.
- 0001609284-26-000004
- Filed
- Aug 11, 2026, 4:27 PM ET
- Trade date
- Aug 7, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 11 derivative transactions. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Saccomano Nicholas ACIK 0001609284 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Class A Common Stock | AGrant or awardAcquired | +150,000 | $0.00 | $0 | 150,000 | Direct | |
| Aug 7, 2026 | Class A Common Stock | DReturned to the companyDisposed | −2,359 | – | – | 0 | Direct | |
| Aug 7, 2026 | Class A Common Stock | AGrant or awardAcquired | +2,359 | – | – | 2,359 | Direct | |
| Aug 7, 2026 | Class A Common Stock | DReturned to the companyDisposed | −1,485 | – | – | 0 | Direct | |
| Aug 7, 2026 | Class A Common Stock | AGrant or awardAcquired | +1,485 | – | – | 1,485 | Direct | |
| Aug 7, 2026 | Class A Common Stock | DReturned to the companyDisposed | −8,449 | – | – | 0 | Direct | |
| Aug 7, 2026 | Class A Common Stock | AGrant or awardAcquired | +8,449 | – | – | 8,449 | Direct | |
| Aug 7, 2026 | Class A Common Stock | DReturned to the companyDisposed | −16,898 | – | – | 0 | Direct | |
| Aug 7, 2026 | Class A Common Stock | AGrant or awardAcquired | +16,898 | – | – | 16,898 | Direct | |
| Aug 7, 2026 | Class A Common Stock | DReturned to the companyDisposed | −542,232 | – | – | 0 | Direct | |
| Aug 7, 2026 | Class A Common Stock | AGrant or awardAcquired | +542,232 | – | – | 542,232 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.